<DOC>
	<DOC>NCT01634984</DOC>
	<brief_summary>Selected 400 cases of women with primary breast cancer who were treated with operation randomly, then detect the expression of CDK5RAP2 of cancer tissue. At the same time randomly selected 100 women with primary breast cancer who were under neoadjuvant chemotherapy. Detect the expression of CDK5RAP2 before and after neoadjuvant chemotherapy.</brief_summary>
	<brief_title>The Diagnostic Technology Applied Research of CDK5RAP2 in Breast Cancer</brief_title>
	<detailed_description>The investigators selected 400 cases of women with primary breast cancer who were treated with operation randomly,then detect the expression of CDK5RAP2 of cancer tissue. At the same time randomly selected 100 women with primary breast cancer who were under neoadjuvant chemotherapy. Detect the expression of CDK5RAP2 before and after neoadjuvant chemotherapy.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1. Provision of informed consent 2. Pathological confirmation of breast cancer 3. Tumor stage(TNM):T24bN03M0 4. ER(+) and/or PR(+). 5. Premenopausal woman. 6. Age≥40 years 7. Measurable disease as per RECIST criteria 8. Karnofsky≥70 9. Laboratory criteria: PLT≥100*109/L WBC≥4000/mm3 HGB≥10g/dl ALT and AST&lt;2*ULN 1. Presence of metastatic disease. 2. Inflammatory breast cancer. 3. Bilateral breast cancer. 4. previous chemotherapy or hormonal therapy for current breast neoplasm. 5. other malignant tumor (concurrent or previous). 6. Pregnant woman. 7. Hypersensitive to any drug in CEF regimen or any ingredient of Zoladex. 8. Any severe systemic disease contraindicating chemotherapy.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>expression of CDK5RAP2</keyword>
</DOC>